Interní Med. 2006; 8(6): 266-269

Pulmonary arterial hypertension in congenital heart disease

MUDr. Pavel Jansa
Centrum pro plicní hypertenzi, II. interní klinika kardiologie a angiologie, VFN a 1. LF UK, Praha

Pulmonary arterial hypertension (PAH) is a heterogeneous group of diseases that share the prekapilary pulmonary hypertension, similar pathophysiology (with vasoconstriction, remodeling of pulmonary arteries and thrombosis) and options of specific pharmacotherapy. In the group of PAH, especially PAH in systemic connective tissue diseases, congenital left-to right shunts, portal hypertension, HIV infection and abuse of certain anorectics are together with idiopathic and familial PAH included. Pulmonary hypertension is present in about 10% of patients with congenital heart disease in adults. Most frequently it is a consequence of recirculation across left to right shunt. Pulmonary hypertension gradually advances, patients become symptomatic, dying in the 3rd to 5th decade of life. Opinions on conventionally used noninvasive treatment strategies (anticoagulation, oxygen therapy, hemodilution) are mostly controversial. Parenteral therapy with prostanoids improves physical endurance and hemodynamics, but has many complications. Heart and lung transplantation or lung transplantation with correction of congenital heart disorder is a solution for strictly selected group of patients after exhaustion of conservative therapy. An option of a specific oral therapy is a great progress of recent years. It was successfully tested mainly in idiopathic PAH and PAH in systemic connective tissue diseases. Last year results of first large randomized clinical trial in patients with Eisenmenger´s syndrome were published. Bosentan treatment (dual antagonist of endothelin receptors) did not worsen the desaturation and lead to improvement of physical endurance and hemodynamics.

Keywords: Key words: pulmonary arterial hypertension, left to right shunt, Eisenmenger´s syndrome, prostanoids, bosentan.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jansa P. Pulmonary arterial hypertension in congenital heart disease. Interní Med. 2006;8(6):266-269.
Download citation

References

  1. Ammash NM, Connolly HM, Abel MD, et al. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol 1999; 33: 222-227. Go to original source... Go to PubMed...
  2. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004; 169: 441-447. Go to original source... Go to PubMed...
  3. Bowyer JJ, Busst CM, Denison DM, et al. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-390. Go to original source... Go to PubMed...
  4. Broberg C, Ujita M, Babu-Narayan S, et al. Massive pulmonary artery thrombosis with heamoptysis in adults with Eisenmenger´s syndrome: a clinical dilemma. Heart 2004; 90: e63. Go to original source... Go to PubMed...
  5. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845-1855. Go to original source... Go to PubMed...
  6. Daniels LB, Krummen DE, Blanchard DG: Echocardiography in pulmonary vascular disease. Cardiol Clin, 2004; 22: 383-399. Go to original source... Go to PubMed...
  7. Farber HW, Loscalzo J. Pulmonary arterial hypertension - mechanism of disease. N Engl J Med, 2004; 351: 1655-1665. Go to original source... Go to PubMed...
  8. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25: 2243-2278. Go to original source... Go to PubMed...
  9. Galie N, Baghetti M, Gatzoulis, et al. BREATHE-5: Bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in Eisenmenger physiology. Chest 2005; 128: 496s-496s. Go to original source...
  10. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005; 353: 2148-2157. Go to original source... Go to PubMed...
  11. Hopkins WE, Ochoa LL, Richardson GW et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105.
  12. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. Go to original source... Go to PubMed...
  13. Rabinovitch M, Keane JF, Fellows KE, et al. Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects. Correlation with hemodynamics data and morphometric findings in lung biopsy tissue. Circulation 1981; 63: 152-164. Go to original source... Go to PubMed...
  14. Rosenzweig EB, Kerstein D, Barst RJ, et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865. Go to original source... Go to PubMed...
  15. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804. Go to original source... Go to PubMed...
  16. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 2004; 43: 5S-12S. Go to original source... Go to PubMed...
  17. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745-755. Go to original source... Go to PubMed...
  18. Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21: 731-737. Go to original source... Go to PubMed...
  19. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958; 2: 701-709, 9: 755-762. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.